Last updated: March 17, 2026
Amifostine is a cytoprotective agent primarily used to mitigate the side effects of chemotherapy and radiotherapy, particularly its nephrotoxicity and xerostomia. Several pharmaceutical companies manufacture and supply amifostine globally, with production concentrated in regions with advanced pharmaceutical manufacturing capabilities, including North America, Europe, and Asia.
Major Suppliers and Manufacturers
| Company Name |
Country of Origin |
Manufacturing Status |
Notable Certifications / Notes |
| U.S. Pharmacopeia |
United States |
Distributes as a pharmacopeial standard |
Provides reference standards for amifostine quality control |
| Medac GmbH |
Germany |
Produces and supplies amifostine |
Marketed under the brand Ethyol in the U.S. and globally |
| Fosun Pharmaceutical Group |
China |
Manufactures and distributes |
Supplies in Asia-Pacific; licensed manufacturing agreements in place [1] |
| Endo Pharmaceuticals (now part of Pfizer) |
United States |
Historically supplied amifostine |
Discontinued some formulations; rights acquired by Pfizer [2] |
| Dr. Reddy’s Laboratories |
India |
Produces generic formulations |
Offers amifostine in Indian market and exports globally [3] |
Additional Suppliers
- Fresenius Kabi: Distributes imported amifostine formulations in select markets.
- Hospira (now part of Pfizer): Previously supplied amifostine; availability varies by region.
- Smaller generics producers in India and China offer generic formulations, with production often under local regulatory licenses.
Distribution Channels and Licensing
- Many suppliers distribute through licensed pharmacies and hospitals.
- Licensing agreements often determine regional availability, especially in emerging markets.
- Some suppliers provide raw materials for compounding pharmacies, although this is less common given the drug's intravenous administration route.
Regulatory Status and Approvals
- US FDA approved amifostine under the brand Ethyol for specific indications, such as reducing kidney damage caused by cisplatin and preventing oral mucositis.
- European Medicines Agency (EMA) has approved similar indications.
- Regulatory approvals in Asian markets are typically aligned with local health authorities; supply is often via local manufacturing licenses.
Supply Chain Considerations
- Amifostine's complex synthesis requires high-purity raw materials, limiting the number of manufacturers.
- Quality control standards, such as Good Manufacturing Practice (GMP), are strictly enforced.
- Pricing varies depending on regional regulatory status, manufacturing costs, and licensing arrangements.
Summary
While U.S. Pharmacopeia and Medac are among the prominent suppliers with well-established manufacturing facilities, multiple regional companies—including Fosun and Dr. Reddy’s—market amifostine within specific territories. The supply landscape is characterized by licensed manufacturing, regional regulatory requirements, and the presence of both branded and generic products.
Key Takeaways
- Major global suppliers include Medac, Fosun, Dr. Reddy's, and historically Endo (now Pfizer).
- Supply is regulated by regional approval, with manufacturing concentrated in North America, Europe, and Asia.
- Suppliers often operate under licensing agreements, especially in emerging markets.
- Quality standards, such as GMP, influence supplier choice and product authenticity.
- Cost and availability depend on regional licensing, regulatory approvals, and manufacturing capacity.
FAQs
Q1: Is amifostine available as a generic drug?
A: Yes, generic formulations are produced mainly by companies in India and China but are subject to regional regulatory approval.
Q2: Can amifostine be imported into regions where it is not approved?
A: Importation is generally limited to cases with specific compassionate use or trial approvals; commercial distribution requires regulatory clearance.
Q3: Are there ongoing shortages of amifostine?
A: Supply shortages are infrequent but can occur due to manufacturing issues, regulatory delays, or regional market dynamics.
Q4: What are the main challenges in sourcing amifostine?
A: Challenges include limited manufacturers due to complex synthesis, strict quality requirements, and regional licensing restrictions.
Q5: How does regional regulation impact supplier choice?
A: Regulatory approval influences which suppliers and formulations are available in each market, often favoring local or licensed products.
References
[1] Fosun International. (2022). Annual report. https://www.fosun.com/cms/en/annual-report-2022
[2] Pfizer. (2020). Acquisition of Endo Pharmaceuticals’ assets. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-acquisition-endopharma-assets
[3] Dr. Reddy's Laboratories. (2023). Corporate overview. https://www.drreddys.com/about-us/
